The medical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a more substantial loss in body size and benefit metabolic markers, particularly c